Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 120,256 | 110,718 | 67,612 | 93,510 | 109,966 |
| Marketable Securities | 368,488 | 439,252 | 442,341 | 427,034 | 264,915 |
| Receivables | N/A | N/A | N/A | N/A | 15,000 |
| Other current assets | 0 | 1,317 | 1,704 | 2,030 | 3,762 |
| TOTAL | $510,268 | $568,715 | $525,407 | $537,253 | $405,317 |
| Non-Current Assets | |||||
| PPE Net | 50,457 | 51,244 | 51,735 | 49,336 | 48,134 |
| Investments And Advances | 362,159 | 361,035 | 192,445 | 224,390 | 61,434 |
| Other Non-Current Assets | 55,151 | 53,848 | 56,434 | 57,272 | 60,874 |
| TOTAL | $467,767 | $466,127 | $300,614 | $330,998 | $170,442 |
| Total Assets | $978,035 | $1,034,842 | $826,021 | $868,251 | $575,759 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,989 | 6,494 | 6,510 | 6,812 | 7,075 |
| Accrued Expenses | 34,867 | 26,530 | 23,780 | 15,997 | 33,864 |
| Other current liabilities | 223 | 633 | 178 | 824 | 524 |
| TOTAL | $67,767 | $66,532 | $62,143 | $56,136 | $85,691 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 13,576 | 20,024 | 19,259 | 22,613 | 37,883 |
| Other Non-Current Liabilities | 72,423 | 73,636 | 74,822 | 75,975 | 77,028 |
| TOTAL | $74,649 | $75,380 | $78,954 | $100,912 | $95,097 |
| Total Liabilities | $142,416 | $141,912 | $141,097 | $157,048 | $180,788 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 64,944 | 64,765 | 61,753 | 61,358 | 61,112 |
| Common Shares | 7 | 7 | 6 | 6 | 6 |
| Retained earnings | -754,610 | -683,858 | -621,371 | -579,309 | -530,752 |
| Other shareholders' equity | -1,485 | 1,931 | -2,099 | -1,777 | -552 |
| TOTAL | $835,619 | $892,930 | $684,924 | $711,203 | $394,971 |
| Total Liabilities And Equity | $978,035 | $1,034,842 | $826,021 | $868,251 | $575,759 |